
ASP Isotopes Inc. targets initial commercial shipments of C-14 and Yb-176 in mid-2026, Si-28 in Q2 2026, and HALEU by 2027. The company anticipates continued significant losses and increased capital.
Bullish
ASP Isotopes Inc. commenced commercial isotope production in 2025, leveraging scalable ASP technology. Strategic acquisitions expanded market reach and diversified revenue streams, supported by strong cash reserves and financing.
Bearish
ASP Isotopes Inc. faces significant net losses and an accumulated deficit, with high regulatory and IP risks for its dual-use technology, no enriched isotope sales, and reliance on few key customers.